131 results about "Bladder cancer" patented technology

The invention provides an organoid chip for screening micro-ecological drugs as well as application and a preparation method of the organoid chip, and relates to the technical field of biological medicines. The invention provides a chip integrating intestinal epithelium, a prostate cancer organ and a bladder cancer organ, which is used for researching how microecological preparations, such as probiotics, metabolites and the like, affect tumor microenvironment and immunotherapy effects. The chip can simulate interaction of intestinal tract-tumor axis, and provides an in-vitro evaluation system for precise tumor immunotherapy.

The invention discloses an engineered artificial vesicle and application of the engineered artificial vesicle in multiple in-situ detection of urine exosome miRNA, and belongs to the field of biosensors. The method comprises the following steps: constructing planar framework nucleic acid simultaneously modified with cholesterol and an aptamer through annealing reaction; a molecular beacon with a fluorophore is designed according to a target gene sequence, and the molecular beacon and a double-strand specific nuclease (DSN) system are jointly encapsulated in an artificial vesicle; the engineered artificial vesicles and a sample to be detected are incubated, the fluorescence modified molecular beacons can specifically recognize target genes, cyclic cutting and signal amplification are achieved under DSN mediation, and the broken molecular beacons release fluorescence signals; all fluorescence signals in the vesicles are collected through a fluorescence imaging technology, and a characteristic fluorescence spectrum of the to-be-detected sample is obtained. According to the present invention, the miRNA heterogeneity analysis at the single vesicle level and the precise multi-target detection of bladder cancer and other diseases can be achieved, and the problems of low throughput, target number limitation and the like of the existing vesicle in-situ detection are effectively overcome.

The invention relates to a urine metabolism combined marker for diagnosing bladder cancer and a screening method of the urine metabolism combined marker. The urine metabolism combined marker is prepared from 2-methyl furan, dimethyl disulfide, octylene and acetophenone. The method for screening the urine metabolism combined marker comprises the following steps: carrying out chromatographic separation and mass spectrometry detection on a urine sample on the basis of a headspace automatic sampler in combination with a chromatographic column and a photochemical ionization time-of-flight mass spectrometry, preprocessing mass spectrometry data, and extracting spectrum peak data of metabolites in urine; the urine metabolism combination marker for diagnosing bladder cancer is obtained through further statistical analysis. The screening method of the urine metabolism combined marker for diagnosing the bladder cancer has the advantages of non-invasiveness, high-throughput detection, simplicity in operation and accurate result, and has a wide application prospect.

The present disclosure relates to a method for treating triple-negative breast cancer or non-muscle-invasive bladder cancer in a subject, comprising administering to the subject a composition comprising nonviable cells of Streptococcus pyogenes and an immune checkpoint inhibitor.

A method for treating bladder cancer is provided at this institution.

The invention discloses a bladder cancer mutation detection and typing method and system using pathomics characteristics, and relates to the technical field of disease detection.The bladder cancer mutation detection and typing method comprises the steps that related data of bladder cancer tissue of a patient is received, and then a bladder cancer tissue pathological section image is subjected to image segmentation to obtain a segmented bladder cancer tissue pathological section image; feature extraction processing is carried out based on the segmented bladder cancer tissue pathological section image to obtain bladder cancer tissue pathological feature data, feature weight weighting processing is carried out based on the bladder cancer tissue pathological feature data to obtain a bladder cancer comprehensive weight coefficient, and the bladder cancer comprehensive weight coefficient is predicted through an ecDNA probability prediction model to obtain an ecDNA probability coefficient; and performing multi-modal space fusion on the ecDNA probability coefficient and bladder cancer tissue gene data to obtain an ecDNA risk score, and finally realizing bladder cancer mutation detection and typing based on the ecDNA risk score.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

The application provides a urine exosome-based bladder cancer gene detection system and application, and relates to the technical field of biological detection. Through the cooperative application of the internal reference gene and the diagnosis model, the application provides a reliable endogenous quality control standard for the bladder tissue-derived exosome in the urine exosome sample; meanwhile, the application realizes non-invasive, accurate, rapid screening, diagnosis, prognosis and recurrence monitoring of bladder cancer, lays a key technical foundation and detection tool for the urine exosome-based molecular diagnosis of bladder cancer, and has important clinical transformation value and application prospect.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

Provided herein are methods of treatment, erdafitinib for use and use of erdafitinib for the treatment of bladder cancer harboring one or more FGFR alterations comprising locally delivering erdafitinib into the bladder of a patient.

The invention discloses a gemcitabine drug sensitive marker, a detection kit and application of the gemcitabine drug sensitive marker, the gemcitabine drug sensitive marker is a gemcitabine drug-resistant marker or / and a gemcitabine sensitive marker, and the gemcitabine drug-resistant marker is one or more of ATOH8, DAPK2, BCL2L2, PNPLA2, SHROOM1, FGGY, CPQ, CPO, SLC10A5, ADAMTS15, COL25A1, ASMTL and ENSG00000286264; the sensitive marker is one or more of FAM163A, KREMEN2, VPS37D, GGCT (Growth Growth Computed Tomography), ADSL (Asymmetrical Digital Subscriber Loop), FOXL2 (Focal OXL2), MAST1 (MAST1), DNAAF3 (Deoxyribose Nucleic Acid Amplified The gemcitabine drug sensitive marker is used for predicting the drug effect of gemcitabine. According to the present invention, the expression of the related molecules is detected through the sequencing of the tissue transcriptome of the urothelial carcinoma patient, or through the PCR, the gene chip, the tissue chip, the NanoString technology, the immunohistochemistry and the ELISA method, and the guidance is provided for the drug use of gemcitabine and the precise treatment of bladder cancer.

The invention discloses an LAMP (loop-mediated isothermal amplification)-based rapid detection primer composition and kit for non-muscle invasive bladder cancer and application of the LAMP-based rapid detection primer composition and kit. The primer composition comprises a primer group for targeted amplification of a VIM gene and a TMEFF2 gene. According to the method, rapid nucleic acid extraction is achieved through a one-step method reagent, enzymatic methylation conversion is combined to replace a traditional bisulfite method, and nucleic acid damage and detection complexity can be remarkably reduced. A double-target detection system is constructed on the basis of VIM and TMEFF2 genes, and visual rapid detection of the non-muscle invasive bladder cancer is realized in combination with an LAMP detection technology. The whole detection process does not need a centrifugal machine or a PCR instrument, extraction, conversion and detection can be completed only through a metal bath or a water bath kettle, operation is easy and convenient, and cost is low. The kit provided by the invention is suitable for household self-test, reduces the detection burden of patients, and has wide clinical and household application prospects.

Provided herein are therapeutic methods for use in treating bladder cancer, the therapeutic methods comprising administration of erdafitinib and drug delivery systems comprising erdafitinib.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

The invention discloses an application of a GABAA alpha 6 receptor knockout substance and a combined drug thereof in preparation of a bladder cancer treatment product. The invention provides an application of a substance for knocking out a GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a tumor treatment product. The invention also provides application of a substance for knocking out the GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a product for inhibiting tumor progression. By knocking out the GABAA alpha6 receptor gene, the regulation effect of the GABAA alpha6 receptor gene on CD8 + T cell functions is researched, the application value of the GABAA alpha6 receptor gene in bladder cancer treatment is verified, and a new strategy is provided for clinical treatment.

The invention relates to application of icaritin in preparation of a medicine for treating bladder cancer. The icaritin shows a good treatment effect in the treatment of bladder cancer regardless of a single drug or a combination of an immunosuppressor and a chemotherapeutic drug.

A method of treating bladder cancer with an agonistic IL-15 complex, alone or in combination with BCG, is described.

The invention relates to an immunohistochemical detection reagent and kit for bladder cancer neuroendocrine subtype diagnosis and prognosis based on a PHF6 index. The reagent comprises a PHF6 primary antibody, a PHF6 secondary antibody, an antigen repair solution, blocking serum, a DAB developing solution, a hematoxylin staining solution, a hydrochloric acid-alcohol differentiation solution, an ammonia water blue-returning solution and a neutral gum mounting medium. The obvious correlation between the expression level of the PHF6 and the neuroendocrine subtype of the bladder cancer is determined by detecting the expression condition of the PHF6 in the bladder cancer tissue and combining a series of cell experiments and clinical pathological analysis. The invention provides a novel and effective diagnosis means which can help a clinician to accurately judge the neuroendocrine subtype of bladder cancer, so that a more accurate individualized treatment scheme is formulated for a patient, and more reliable prognosis evaluation is provided.

The application discloses a bladder cancer diagnosis and treatment integrated system and a control method thereof, which comprises a swept-frequency OCT light source, a treatment laser, a wavelength division multiplexer, a double-clad optical fiber, a flexible scanning probe, an endoscope imaging unit and an intelligent image processing and control terminal; imaging light and treatment laser are transmitted in a common light path by using the double-clad optical fiber, and scanning and light beam control are completed by means of a double-axis MEMS micro-mirror. The control method obtains tomographic structure information and depth information by reconstructing OCT data, and controls treatment laser power, galvanometer deflection and laser pause, recovery or stop by combining distance calculation, displacement compensation and blood perfusion monitoring, and is suitable for imaging navigation and closed-loop treatment in bladder cancer surgery.

Described herein are methods for treating high-risk non-muscle-invasive bladder cancer (HR-NMIBC) that involve administering a fibroblast growth factor receptor (FGFR) inhibitor. Also described are methods for treating intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) that involve administering an FGFR inhibitor.

Identifying the causes of haematuria requires detailed clinical investigations. Unbalanced patient populations (mostly male) and diverse causes complicate patient classification and biomarker identification. Multi-marker analysis with advanced methods can improve diagnosis even in unbalanced datasets. We used k-means clustering, decision trees, random forest with LIME explainer, and CACTUS algorithm to classify patients as healthy (with no clear cause of haematuria) or sick (with an identified cause of haematuria e.g., bladder cancer, or infection). The CACTUS algorithm was more robust to dataset imbalance, achieving balanced accuracy of 0.747 for both genders, 0.718 for females, and 0.803 for males. Key biomarkers identified included microalbumin, male gender, and tPSA for the whole dataset; age, microalbumin, tPSA, cystatin C, BTA, HAD, and S100A4 for males; and microalbumin, IL-8, pERK, and CXCL16 for females. CACTUS outperformed decision trees and random forest, highlighting potential novel biomarkers for future diagnosis.

The invention discloses a bladder cancer combined treatment method based on CTSE enhancement. According to the application, research finds that CTSE is a key factor related to ICB reaction and patient survival rate improvement. Functional studies find that CTSE improves the curative effect of ICB by enhancing MHC expression, so that antigen presentation, T cell activation and anti-tumor immunity are promoted, and the anti-inflammatory phenotype of macrophages is adjusted at the same time. Importantly, overexpression of the CTSE can further enhance the immunoreaction for blocking the PD-1, has the effect of synergistically treating the bladder cancer, and provides a new idea for effective treatment of the bladder cancer.

The present invention relates to a method of prognosis of a subject affected by bladder cancer comprising determining the expression level of a set of genes in an isolated sample from said subject and to kits for performing said method.

The invention discloses a UMOD antibody, a sialidase NEU3 fusion protein and application thereof.The UMOD antibody is invented firstly, VL-CL and VH-CH1 nucleotide sequences of a Fab fragment of the UMOD antibody and a nucleotide sequence of a sialidase NEU3 functional area peptide fragment are used for constructing a recombinant vector, then the recombinant vector is expressed and purified to obtain the fusion protein, and the fusion protein is directly administrated through a bladder to treat bladder cancer. The sialidase NEU3 can identify the UMOD antigen, can play a role in degrading sialic acid of the sialidase NEU3, can significantly inhibit the growth of bladder cancer, and has the advantages of simple operation and good treatment effect.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

To provide a combination chemotherapy exhibiting a large therapeutic effect on cancer, especially bladder cancer.SOLUTION: There is provided a first chemotherapeutic agent and a second chemotherapeutic agent for use in the treatment of cancer, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of a peptide of at least 10 amino acids comprising an alpha-helical structure and oleic acid or oleate in a ratio of at least 3 oleic acid or oleate molecules per peptide molecule. Provided are either a first chemotherapeutic agent or a second chemotherapeutic agent for use in cancer therapy, for use in conjunction with other chemotherapeutic agents, pharmaceutical compositions related thereto, and methods of treatment.SELECTED DRAWING: None

This invention relates to gene constructs, expression cassettes comprising said gene constructs, and oncolytic viruses, and their use in methods for treating, preventing, or alleviating cancer. The gene constructs, expression cassettes, and oncolytic viruses are particularly useful (but not limited to) for treating bladder cancer, such as non-muscle-invasive bladder cancer.